I50 I35 F03 I21
Conditions
Interventions
Group 1: Patients with acute cardiac decompensation in the context of a myocardial infarction
Group 2: Patients with planned TAVI (trans aortic valve implantation)
Group 3: Patients with chronic heart
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patient has signed the informed consent form for participation in the study
Exclusion criteria
Exclusion criteria: Surgery or catheter-based procedures (e.g. PCI, transcatheter edge-to-edge mitral or tricuspid valve repair) planned in the next 3 months after study inclusion. PCI may be performed immediately prior to study inclusion and prior to TAVI. Women of childbearing age (pregnancy and breastfeeding) Known active malignant disease with a life expectancy 3)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive impairment measured by neuropsychological testing at the following time points: Arm 1: Day 3-5 after acute myocardial infarction, 1 month, 6 months, 12 months. Arm 2: Before TAVI, 1 month, 6 months, 12 months after TAVI Arm 3: Inclusion date, 1 month, 6 months, 12 months Arm 4: Inclusion date, 1 month, 6 months, 12 months Scores: MoCA (Montreal Cognitive Assessment) MMST (Mini Mental Status Examination) CERAD-Testbatterie (mit Wortliste A) RWT (Sportarten-Früchte; G-R) Rey-Figur (Abzeichnen) ZN / ZNR Rey-Figur (GD I) Uhrentest (Shulman) TAP: Alertness, GoNogo Bed. 1; Geteilte Aufmerksamkeit Rey-Figur (GD II) MWT-B (nur bei Einschluss) BDI-II | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of neurodegeneration markers, e.g. total tau protein, neurofilament light chain | — |
Countries
Germany
Contacts
Public ContactSteffen Uhr
Universitätsmedizin Göttingen
Outcome results
None listed